Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective
There are currently no assessment tools that focus on evaluating patients with multiple sclerosis (MS) who are experiencing a relapse or that evaluate patients' response to acute relapse treatment. In practice, assessments are often subjective, potentially resulting in overlooked symptoms, unad...
Saved in:
| Published in: | International journal of MS care Vol. 14; no. 3; p. 148 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.01.2012
|
| ISSN: | 1537-2073 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | There are currently no assessment tools that focus on evaluating patients with multiple sclerosis (MS) who are experiencing a relapse or that evaluate patients' response to acute relapse treatment. In practice, assessments are often subjective, potentially resulting in overlooked symptoms, unaddressed patient concerns, unnoticed or underrecognized side effects of therapies (both disease modifying and symptomatic), and suboptimal therapeutic response. Systematic evaluation of specific symptoms and potential side effects can minimize the likelihood of overlooking important information. However, given the number of potential symptoms and adverse events that patients may experience, an exhaustive evaluation can be time-consuming. Clinicians are thus challenged to balance thoroughness with brevity. A need exists for a brief but comprehensive objective assessment tool that can be used in practice to 1) help clinicians assess patients when they present with symptoms of a relapse, and 2) evaluate outcomes of acute management. A working group of expert nurses convened to discuss recognition and management of relapses. In this article, we review data related to recognition and management of relapses, discuss practical challenges, and describe the development of an assessment questionnaire that evaluates relapse symptoms, the impact of symptoms on the patient, and the effectiveness and tolerability of acute treatment. The questionnaire is designed to be appropriate for use in MS specialty clinics, general neurology practices, or other practice settings and can be administered by nurses, physicians, other clinicians, or patients (self-evaluation). The relapse assessment questionnaire is currently being piloted in a number of practice settings. |
|---|---|
| AbstractList | There are currently no assessment tools that focus on evaluating patients with multiple sclerosis (MS) who are experiencing a relapse or that evaluate patients' response to acute relapse treatment. In practice, assessments are often subjective, potentially resulting in overlooked symptoms, unaddressed patient concerns, unnoticed or underrecognized side effects of therapies (both disease modifying and symptomatic), and suboptimal therapeutic response. Systematic evaluation of specific symptoms and potential side effects can minimize the likelihood of overlooking important information. However, given the number of potential symptoms and adverse events that patients may experience, an exhaustive evaluation can be time-consuming. Clinicians are thus challenged to balance thoroughness with brevity. A need exists for a brief but comprehensive objective assessment tool that can be used in practice to 1) help clinicians assess patients when they present with symptoms of a relapse, and 2) evaluate outcomes of acute management. A working group of expert nurses convened to discuss recognition and management of relapses. In this article, we review data related to recognition and management of relapses, discuss practical challenges, and describe the development of an assessment questionnaire that evaluates relapse symptoms, the impact of symptoms on the patient, and the effectiveness and tolerability of acute treatment. The questionnaire is designed to be appropriate for use in MS specialty clinics, general neurology practices, or other practice settings and can be administered by nurses, physicians, other clinicians, or patients (self-evaluation). The relapse assessment questionnaire is currently being piloted in a number of practice settings.There are currently no assessment tools that focus on evaluating patients with multiple sclerosis (MS) who are experiencing a relapse or that evaluate patients' response to acute relapse treatment. In practice, assessments are often subjective, potentially resulting in overlooked symptoms, unaddressed patient concerns, unnoticed or underrecognized side effects of therapies (both disease modifying and symptomatic), and suboptimal therapeutic response. Systematic evaluation of specific symptoms and potential side effects can minimize the likelihood of overlooking important information. However, given the number of potential symptoms and adverse events that patients may experience, an exhaustive evaluation can be time-consuming. Clinicians are thus challenged to balance thoroughness with brevity. A need exists for a brief but comprehensive objective assessment tool that can be used in practice to 1) help clinicians assess patients when they present with symptoms of a relapse, and 2) evaluate outcomes of acute management. A working group of expert nurses convened to discuss recognition and management of relapses. In this article, we review data related to recognition and management of relapses, discuss practical challenges, and describe the development of an assessment questionnaire that evaluates relapse symptoms, the impact of symptoms on the patient, and the effectiveness and tolerability of acute treatment. The questionnaire is designed to be appropriate for use in MS specialty clinics, general neurology practices, or other practice settings and can be administered by nurses, physicians, other clinicians, or patients (self-evaluation). The relapse assessment questionnaire is currently being piloted in a number of practice settings. There are currently no assessment tools that focus on evaluating patients with multiple sclerosis (MS) who are experiencing a relapse or that evaluate patients' response to acute relapse treatment. In practice, assessments are often subjective, potentially resulting in overlooked symptoms, unaddressed patient concerns, unnoticed or underrecognized side effects of therapies (both disease modifying and symptomatic), and suboptimal therapeutic response. Systematic evaluation of specific symptoms and potential side effects can minimize the likelihood of overlooking important information. However, given the number of potential symptoms and adverse events that patients may experience, an exhaustive evaluation can be time-consuming. Clinicians are thus challenged to balance thoroughness with brevity. A need exists for a brief but comprehensive objective assessment tool that can be used in practice to 1) help clinicians assess patients when they present with symptoms of a relapse, and 2) evaluate outcomes of acute management. A working group of expert nurses convened to discuss recognition and management of relapses. In this article, we review data related to recognition and management of relapses, discuss practical challenges, and describe the development of an assessment questionnaire that evaluates relapse symptoms, the impact of symptoms on the patient, and the effectiveness and tolerability of acute treatment. The questionnaire is designed to be appropriate for use in MS specialty clinics, general neurology practices, or other practice settings and can be administered by nurses, physicians, other clinicians, or patients (self-evaluation). The relapse assessment questionnaire is currently being piloted in a number of practice settings. |
| Author | Ross, Amy Perrin Harris, Colleen J Halper, June |
| Author_xml | – sequence: 1 givenname: Amy Perrin surname: Ross fullname: Ross, Amy Perrin organization: Department of Neurosciences, Loyola University Chicago, Chicago, IL, USA (APR); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (JH); and Department of Clinical Neurosciences-Multiple Sclerosis Clinic, University of Calgary, Alberta, Canada (CJH) – sequence: 2 givenname: June surname: Halper fullname: Halper, June organization: Department of Neurosciences, Loyola University Chicago, Chicago, IL, USA (APR); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (JH); and Department of Clinical Neurosciences-Multiple Sclerosis Clinic, University of Calgary, Alberta, Canada (CJH) – sequence: 3 givenname: Colleen J surname: Harris fullname: Harris, Colleen J organization: Department of Neurosciences, Loyola University Chicago, Chicago, IL, USA (APR); Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (JH); and Department of Clinical Neurosciences-Multiple Sclerosis Clinic, University of Calgary, Alberta, Canada (CJH) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24453746$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9UMtOwzAQ9KGIPuAHOCAfuaTYjhPH3KqKl1SJC5wrx9mAUeIYrwPi74mg5TQ7O6PRaJZk5gcPhFxwtlZCyGte5CoTTOUZl-t8zWU1I4v_55wsEd8Zywuu8lMyF1JOkiwXZNggAqLzrzRCZ8JEqPHNRDAMHoGm4SjQFMGkHnyiztNgkptOpF8uvdF-7JILHVC0HcQBHd5QQ_0Yf5MDRAxgk_uEM3LSmg7h_IAr8nJ3-7x9yHZP94_bzS4LnHOWFbUoyrpqdCtg6lnWUEmjitLwVlW2LQSvFWN1rXOtjNW2qaxqWi21BaiErsWKXP3lhjh8jIBp3zu00HXGwzDinkstSs0qySfr5cE61j00-xBdb-L3_jiS-AFTt2vY |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.7224/1537-2073-14.3.148 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 24453746 |
| Genre | Journal Article |
| GroupedDBID | 2QV 2WC 53G AAWTL ACGFO ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL DIK E3Z EBS EIHBH EJD FRP GX1 HYE NPM OK1 RPM TR2 Y3D 7X8 |
| ID | FETCH-LOGICAL-p1110-5b256b8d9f2e7466be84a756a1f78cf521b700bb9397ac9cd8c7df949cee829b2 |
| IEDL.DBID | 7X8 |
| ISSN | 1537-2073 |
| IngestDate | Fri Jul 11 11:26:36 EDT 2025 Thu Jan 02 22:16:05 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p1110-5b256b8d9f2e7466be84a756a1f78cf521b700bb9397ac9cd8c7df949cee829b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 24453746 |
| PQID | 1492690841 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1492690841 pubmed_primary_24453746 |
| PublicationCentury | 2000 |
| PublicationDate | 20120101 |
| PublicationDateYYYYMMDD | 2012-01-01 |
| PublicationDate_xml | – month: 1 year: 2012 text: 20120101 day: 1 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | International journal of MS care |
| PublicationTitleAlternate | Int J MS Care |
| PublicationYear | 2012 |
| References | 21622592 - Mult Scler. 2011 Oct;17(10):1218-24 18550183 - Trends Neurosci. 2008 Jul;31(7):353-60 15198439 - Can J Neurol Sci. 2004 May;31(2):157-68 17350047 - J Neurol Sci. 2007 May 15;256 Suppl 1:S34-8 21242498 - Neurology. 2011 Jan 18;76(3):294-300 21455066 - Curr Opin Neurol. 2011 Jun;24(3):224-9 19066192 - J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):400-3 2544829 - Neurology. 1989 Jul;39(7):969-71 20028710 - Mult Scler. 2010 Feb;16(2):228-37 21403003 - Arch Neurol. 2011 Jul;68(7):870-8 9620667 - J Leukoc Biol. 1998 Jun;63(6):740-5 2984332 - J Neurol Neurosurg Psychiatry. 1985 Feb;48(2):157-9 12429716 - J Leukoc Biol. 2002 Nov;72(5):946-52 14759626 - J Neurol Sci. 2004 Mar 15;218(1-2):3-7 18290849 - Eur J Neurol. 2008 Mar;15(3):284-8 20534650 - Brain. 2010 Jul;133(Pt 7):1914-29 20421572 - Neurology. 2010 Apr 27;74 Suppl 3:S8-15 15001661 - Pharmacol Rev. 2004 Mar;56(1):1-29 19378717 - Can J Neurol Sci. 2009 Mar;36(2):213-5 9150809 - Acta Neurol Scand. 1997 Apr;95(4):201-7 19131851 - Neurologist. 2009 Jan;15(1):1-5 7912347 - Lancet. 1994 Jul 2;344(8914):9-13 11882048 - Clin Exp Immunol. 2002 Jan;127(1):165-71 18204919 - J Neurol. 2008 Feb;255(2):280-7 15327039 - Mult Scler. 2004 Aug;10(4):413-6 1734247 - N Engl J Med. 1992 Feb 27;326(9):581-8 15623669 - Neurology. 2004 Dec 28;63(12 Suppl 6):S33-40 19678753 - Curr Med Res Opin. 2009 Oct;25(10):2459-70 17346748 - J Neurol Sci. 2007 May 15;256 Suppl 1:S19-22 21384163 - J Neurol. 2011 Sep;258(9):1603-8 20086019 - Mult Scler. 2010 May;16(5):604-10 21439448 - Neurol Clin. 2011 May;29(2):389-400 21561957 - Mult Scler. 2011 Jul;17(7):851-66 8148458 - Clin Infect Dis. 1994 Jan;18 Suppl 1:S79-83 17346747 - J Neurol Sci. 2007 May 15;256 Suppl 1:S5-13 1619410 - J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):450-3 20202650 - J Neurol Sci. 2010 May 15;292(1-2):52-6 21792296 - Drug Des Devel Ther. 2011;5:381-9 17595227 - Endocrinology. 2007 Oct;148(10):4918-26 3511404 - Neurology. 1986 Feb;36(2):238-43 6264409 - Peptides. 1980 Summer;1(2):135-8 2540005 - Eur Neurol. 1989;29(1):10-4 8229035 - J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1219-20 10589540 - Ann Neurol. 1999 Dec;46(6):878-86 7915989 - Eur Neurol. 1994;34(4):199-203 19588409 - Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006921 18796075 - Eur J Neurol. 2008 Sep;15(9):893-908 17350045 - J Neurol Sci. 2007 May 15;256 Suppl 1:S29-33 9633736 - Neurology. 1998 Jun;50(6):1833-6 16324087 - Eur J Neurol. 2005 Dec;12(12):939-46 11034713 - Cochrane Database Syst Rev. 2000;(4):CD001331 2549450 - Neurology. 1989 Sep;39(9):1143-9 19949030 - Neurology. 2009 Dec 1;73(22):1842-8 19890070 - Neurology. 2009 Nov 17;73(20):1616-23 21301327 - Clin Neuropharmacol. 2011 Mar-Apr;34(2):84-9 19221292 - Neurology. 2009 Feb 17;72(7):602-8 6541311 - Neurology. 1984 Oct;34(10):1368-72 4314823 - Neurology. 1970 May;20(5):1-59 21803120 - Mol Cell Endocrinol. 2012 Jan 2;348(1):47-54 15452302 - Neurology. 2004 Sep 28;63(6):1079-80 9093250 - Lancet. 1997 Mar 29;349(9056):902-6 20194583 - Mult Scler. 2010 May;16(5):566-75 19671367 - Int MS J. 2009 Jun;16(2):42-6 12356200 - Mult Scler. 2002 Oct;8(5):359-65 21387374 - Ann Neurol. 2011 Feb;69(2):292-302 6685237 - Neurology. 1983 Nov;33(11):1444-52 9218248 - Neuroimmunomodulation. 1996 Sep-Oct;3(5):259-84 10050902 - Brain. 1999 Jan;122 ( Pt 1):141-59 18578273 - J Neurosci Nurs. 2008 Jun;40(3):150-7 17376487 - J Neurol Sci. 2007 Aug 15;259(1-2):118-22 3295122 - J Neurol Neurosurg Psychiatry. 1987 May;50(5):511-6 18684216 - Acta Neurol Scand. 2009 Feb;119(2):126-30 9804112 - J Neurol Sci. 1998 Sep 18;160(1):16-25 10844776 - J Clin Neurosci. 1999 Sep;6(5):382-384 14474011 - Lancet. 1961 Nov 18;2(7212):1120-2 15607213 - J Neurol Sci. 2005 Jan 15;228(1):71-4 11886358 - Acta Neurol Scand. 2002 Mar;105(3):164-8 11176941 - Arch Neurol. 2001 Jan;58(1):91-7 14663037 - Neurology. 2003 Dec 9;61(11):1528-32 |
| References_xml | – reference: 14759626 - J Neurol Sci. 2004 Mar 15;218(1-2):3-7 – reference: 18550183 - Trends Neurosci. 2008 Jul;31(7):353-60 – reference: 9218248 - Neuroimmunomodulation. 1996 Sep-Oct;3(5):259-84 – reference: 17350045 - J Neurol Sci. 2007 May 15;256 Suppl 1:S29-33 – reference: 17346747 - J Neurol Sci. 2007 May 15;256 Suppl 1:S5-13 – reference: 6264409 - Peptides. 1980 Summer;1(2):135-8 – reference: 15198439 - Can J Neurol Sci. 2004 May;31(2):157-68 – reference: 20202650 - J Neurol Sci. 2010 May 15;292(1-2):52-6 – reference: 20028710 - Mult Scler. 2010 Feb;16(2):228-37 – reference: 19890070 - Neurology. 2009 Nov 17;73(20):1616-23 – reference: 10050902 - Brain. 1999 Jan;122 ( Pt 1):141-59 – reference: 15623669 - Neurology. 2004 Dec 28;63(12 Suppl 6):S33-40 – reference: 17595227 - Endocrinology. 2007 Oct;148(10):4918-26 – reference: 20194583 - Mult Scler. 2010 May;16(5):566-75 – reference: 12356200 - Mult Scler. 2002 Oct;8(5):359-65 – reference: 21803120 - Mol Cell Endocrinol. 2012 Jan 2;348(1):47-54 – reference: 20421572 - Neurology. 2010 Apr 27;74 Suppl 3:S8-15 – reference: 2540005 - Eur Neurol. 1989;29(1):10-4 – reference: 19588409 - Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006921 – reference: 9150809 - Acta Neurol Scand. 1997 Apr;95(4):201-7 – reference: 12429716 - J Leukoc Biol. 2002 Nov;72(5):946-52 – reference: 9633736 - Neurology. 1998 Jun;50(6):1833-6 – reference: 4314823 - Neurology. 1970 May;20(5):1-59 – reference: 2544829 - Neurology. 1989 Jul;39(7):969-71 – reference: 10844776 - J Clin Neurosci. 1999 Sep;6(5):382-384 – reference: 7915989 - Eur Neurol. 1994;34(4):199-203 – reference: 6541311 - Neurology. 1984 Oct;34(10):1368-72 – reference: 11886358 - Acta Neurol Scand. 2002 Mar;105(3):164-8 – reference: 11034713 - Cochrane Database Syst Rev. 2000;(4):CD001331 – reference: 21792296 - Drug Des Devel Ther. 2011;5:381-9 – reference: 15001661 - Pharmacol Rev. 2004 Mar;56(1):1-29 – reference: 18204919 - J Neurol. 2008 Feb;255(2):280-7 – reference: 15607213 - J Neurol Sci. 2005 Jan 15;228(1):71-4 – reference: 14663037 - Neurology. 2003 Dec 9;61(11):1528-32 – reference: 21622592 - Mult Scler. 2011 Oct;17(10):1218-24 – reference: 3295122 - J Neurol Neurosurg Psychiatry. 1987 May;50(5):511-6 – reference: 17376487 - J Neurol Sci. 2007 Aug 15;259(1-2):118-22 – reference: 19378717 - Can J Neurol Sci. 2009 Mar;36(2):213-5 – reference: 17346748 - J Neurol Sci. 2007 May 15;256 Suppl 1:S19-22 – reference: 9093250 - Lancet. 1997 Mar 29;349(9056):902-6 – reference: 20534650 - Brain. 2010 Jul;133(Pt 7):1914-29 – reference: 8229035 - J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1219-20 – reference: 1619410 - J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):450-3 – reference: 19678753 - Curr Med Res Opin. 2009 Oct;25(10):2459-70 – reference: 18578273 - J Neurosci Nurs. 2008 Jun;40(3):150-7 – reference: 21439448 - Neurol Clin. 2011 May;29(2):389-400 – reference: 21242498 - Neurology. 2011 Jan 18;76(3):294-300 – reference: 19221292 - Neurology. 2009 Feb 17;72(7):602-8 – reference: 11176941 - Arch Neurol. 2001 Jan;58(1):91-7 – reference: 18796075 - Eur J Neurol. 2008 Sep;15(9):893-908 – reference: 9804112 - J Neurol Sci. 1998 Sep 18;160(1):16-25 – reference: 15327039 - Mult Scler. 2004 Aug;10(4):413-6 – reference: 7912347 - Lancet. 1994 Jul 2;344(8914):9-13 – reference: 21387374 - Ann Neurol. 2011 Feb;69(2):292-302 – reference: 6685237 - Neurology. 1983 Nov;33(11):1444-52 – reference: 21301327 - Clin Neuropharmacol. 2011 Mar-Apr;34(2):84-9 – reference: 17350047 - J Neurol Sci. 2007 May 15;256 Suppl 1:S34-8 – reference: 14474011 - Lancet. 1961 Nov 18;2(7212):1120-2 – reference: 15452302 - Neurology. 2004 Sep 28;63(6):1079-80 – reference: 20086019 - Mult Scler. 2010 May;16(5):604-10 – reference: 2549450 - Neurology. 1989 Sep;39(9):1143-9 – reference: 11882048 - Clin Exp Immunol. 2002 Jan;127(1):165-71 – reference: 21561957 - Mult Scler. 2011 Jul;17(7):851-66 – reference: 21403003 - Arch Neurol. 2011 Jul;68(7):870-8 – reference: 19949030 - Neurology. 2009 Dec 1;73(22):1842-8 – reference: 16324087 - Eur J Neurol. 2005 Dec;12(12):939-46 – reference: 21384163 - J Neurol. 2011 Sep;258(9):1603-8 – reference: 18290849 - Eur J Neurol. 2008 Mar;15(3):284-8 – reference: 10589540 - Ann Neurol. 1999 Dec;46(6):878-86 – reference: 21455066 - Curr Opin Neurol. 2011 Jun;24(3):224-9 – reference: 19671367 - Int MS J. 2009 Jun;16(2):42-6 – reference: 8148458 - Clin Infect Dis. 1994 Jan;18 Suppl 1:S79-83 – reference: 19066192 - J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):400-3 – reference: 2984332 - J Neurol Neurosurg Psychiatry. 1985 Feb;48(2):157-9 – reference: 3511404 - Neurology. 1986 Feb;36(2):238-43 – reference: 9620667 - J Leukoc Biol. 1998 Jun;63(6):740-5 – reference: 1734247 - N Engl J Med. 1992 Feb 27;326(9):581-8 – reference: 19131851 - Neurologist. 2009 Jan;15(1):1-5 – reference: 18684216 - Acta Neurol Scand. 2009 Feb;119(2):126-30 |
| SSID | ssj0035173 |
| Score | 1.8081139 |
| Snippet | There are currently no assessment tools that focus on evaluating patients with multiple sclerosis (MS) who are experiencing a relapse or that evaluate... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 148 |
| Title | Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24453746 https://www.proquest.com/docview/1492690841 |
| Volume | 14 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA7qiHhxX8aNCF6jbZNm8SIiDh6cYQ4KcytJmsJc2mpHf78vbTpzEgQvhbS0DcnL-7635AWhG2FAMnSegm3CHfEITTRVlgD3l5xxQ2PbVtd_FZOJnM3UNDjcmpBW2evEVlHnlfU-8rvYV7ZTkWTxQ_1B_KlRProajtBYRwMKVMandInZMopA0y7CDItagDQI2m2aEYBad8t7JGa3FPSF_J1itlAz2v1vJ_fQTiCZ-LGTin205soDtDUOYfRDVHWhXkAt7Pey1NDAusyh0SbMOryo-gd4mYmO5yUOVVgb7N23uE9GxA38BdB23txjjUMyAa5X2ziP0Pvo-e3phYSTF0gNui8iqQEmZGSuisQJxrlxkmmRch0XQtoCIN-IKDJGAZvRVvn6AiIvFFMAuTJRJjlGG2VVulOEGXUMTD7HLQVTFD4aOeuiQscmVUkeR0N03Q9lBpLtwxW6dNVXk60Gc4hOuvnI6q4ERwakBCaQ8bM_vH2OtoHlJJ3f5AINCljX7hJt2u_FvPm8akUGrpPp-AeRpcu_ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessing+relapses+and+response+to+relapse+treatment+in+patients+with+multiple+sclerosis%3A+a+nursing+perspective&rft.jtitle=International+journal+of+MS+care&rft.au=Ross%2C+Amy+Perrin&rft.au=Halper%2C+June&rft.au=Harris%2C+Colleen+J&rft.date=2012-01-01&rft.issn=1537-2073&rft.volume=14&rft.issue=3&rft.spage=148&rft_id=info:doi/10.7224%2F1537-2073-14.3.148&rft_id=info%3Apmid%2F24453746&rft_id=info%3Apmid%2F24453746&rft.externalDocID=24453746 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-2073&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-2073&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-2073&client=summon |